The drug belonging to the DPI group administered in hard capsules consists of the ingredients indacaterol/glycopyrronium/mometasone (114 µg / 46 µg / 68 µg). This fixed tri-therapy is used in patients with insufficiently controlled asthma with a combination of a long-acting beta-2 agonist (LABA) and a high dose of an inhaled corticosteroid (ICS) as maintenance therapy and in which at least one exaceration occurred in the previous year. After 26 weeks of treatment, the maximum air volume that patients could exhale in one second improved by 65 ml, as opposed to patients who inhaled the bi-therapy with indacaterol and mometasone in the same dosage as DPI.
EU approval of the first triple combination for asthma
Jul 22, 2020 | Medicines